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Cancer chemotherapy is often restricted by adverse systemic toxi-
city and the appearance of multidrug resistance. Improvements,
particularly for the treatment of common solid tumours, have been
difficult to realise (Connors, 1996) and as a result combination
therapies designed to increase active drug concentration in the
tumour have been developed; namely antibody-directed enzyme
prodrug therapy (ADEPT) (Bagshawe, 1987; Melton et al, 1996)
and viral/gene-directed enzyme prodrug therapy (V/GDEPT)
(Ram et al, 1993). Here we describe polymer-directed enzyme
prodrug therapy (PDEPT), a novel two-step antitumour approach
combining a polymeric prodrug and polymer-enzyme to generate
cytotoxic drug at the tumour site (Figure 1). Conceptually, PDEPT
proposes initial administration of the polymeric prodrug to
promote tumour targetting before administration of the activating
polymer-enzyme conjugate. 
Polymer-enzyme conjugates such as polyethylene glycol
(PEG)-L-asparaginase (Oncaspar®) have already been developed
to the market (Ho et al, 1986). PEGylation of proteins reduces
their immunogenicity and prolongs circulation time (Delgado 
et al, 1992). Although a new departure in cancer chemotherapy,
several polymer-drug conjugates are already in early clinical trial
(reviewed in Duncan, 1992; Duncan et al, 1996; Brocchini and
Duncan, 1999). These include the N-(2-hydroxypropyl)methacry-
lamide (HPMA) copolymer anticancer conjugates PK1 (FCE
28068) (Vasey et al, 1999), PK2 (FCE 28069) (Ferry et al, 1999)
and PNU (166945) (Ten Bokkel Hunink et al, 1998) and a PEG-
camptothecin conjugate (Pendri et al, 1998). Reduced toxicity and
activity in chemotherapy refractory patients has been described. In
phase I HPMA copolymer-doxorubicin (dox) (PK1) (Figure 2A)
displayed a maximum tolerated dose of 320 mg/m2 (Vasey et al,
1999) and also showed antitumour activity. Moreover the 
clinical pharmacokinetics (PK1 t1/2α = 1.8 h with no dose depen-
dency of clearance) were very similar to those reported in 
animals (Seymour et al, 1990). Combination of polymer-drug and
polymer-enzyme conjugates can capitalise on the ability of both to
target solid tumour tissue passively by a mechanism termed the
enhanced permeability and retention (EPR) effect (Matsumura and
Maeda, 1986). This occurs due to the poorly organised tumour
vasculature (Dvorak et al, 1988; Skinner et al, 1990) resulting in
‘enhanced permeability’ towards circulating molecules. The lack
of lymphatic drainage in tumour tissue leads to increased ‘reten-
tion’. The aim of this study was to establish the feasibility of the
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PDEPT concept using PK1 and HPMA copolymer-cathepsin B as
a model combination. PK1 has proven ability to target solid
tumours by the EPR effect (Seymour et al, 1994) with concomitant
renal elimination resulting in low blood levels within 1–5h  i n
animals and man (Seymour et al, 1990; Vasey et al, 1999). HPMA
copolymer-cathepsin B (Figure 2B) was selected for PK1 activa-
tion as the PK1 Gly-Phe-Leu-Gly polymer-dox linker was
designed to permit intralysosomal dox liberation due to action of
the lysosomal cysteine proteases (Duncan et al, 1984). First it was
necessary to prepare an HPMA copolymer-cathepsin B conjugate
that would retain sufficient enzyme activity after conjugation.
Activity was monitored in vitro using a low molecular weight
substrate N-Benzoyl-Phe-Val-Arg-p-nitroanilide hydrochloride
(Bz-Phe-Val-Arg-NAp) and the polymeric substrate PK1. The
biodistribution of 125I-labelled HPMA copolymer-cathepsin B and
125I-labelled cathepsin B was assessed in mice bearing subcuta-
neous (s.c.) B16F10 tumours and this model was also used to
measure the kinetics of doxorubicin release after intravenous (i.v.)
administration of PK1 alone (drug liberation by endogenous lyso-
somal enzymes) or PK1 followed, after 5 h, by HPMA copolymer-
cathepsin B. Preliminary studies were conducted to establish the
antitumour activity of PDEPT combination using the B16F10 model
and a human non-small-cell lung carcinoma xenograft (COR-L23). 
MATERIALS AND METHODS 
Materials 
Cathepsin B (EC 3.4.22.1) from bovine spleen, reduced glutathione,
Bz-Phe-Val-Arg-NAp, EDTA, Cu(II) sulphate pentahydrate 4% w/v
solution, bicinchoninic acid solution, barbitone buffer (B6632)
were all purchased from Sigma (Dorset, UK). Doxorubicin
hydrochloride (dox) was obtained from Aldrich Chem (UK).
Daunomycin hydrochloride (dnm) was kindly donated by Rhone
Poulence (France). Tris-HCl 0.5 M, pH 6.8, Tris-HCl 1.5 M, pH
8.8, sodium dodecyl sulphate (SDS) 10% (w/v), TEMED, 10%
(w/v) ammonium persulfate, mercaptoethanol, bromophenol blue
and 30% (w/v) 19:1 acrylamide/bis-acrylamide were purchased
from Bio-Rad (UK). PK1 was synthesised as previously described
(Rihova et al, 1989) and batches had the following characteristics:
Mw ~ 30,000 Da; Mw/Mn~1.3; 6–8% w/w of dox content. HPMA
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Figure 2 Structures of (A) PK1 and (B) HPMA copolymer-Gly-Gly-
cathepsin B 
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copolymer-Gly-Gly-p-nitrophenol (ONp) was obtained from
Polymer Laboratories (Church Stretton, UK). 
The cell line B16F10 murine melanoma was kindly donated by
Prof Ian Hart (St Thomas’ Hospital, London, UK). COR-L23 non-
small-cell lung carcinoma human xenograft cell line was
purchased from ECCAC (European Collection of Cell Cultures,
Centre for Applied Biology, Microbiology and Research,
Salisbury, Wiltshire, UK). Bantin and Kingman Ltd (Hull, UK)
supplied the C57 black male mice, Balb/C male mice and nu/nu
male mice. 
Synthesis and characterisation of HPMA copolymer-
cathepsin B 
Cathepsin B was bound to HPMA copolymer-Gly-Gly-ONp using
a non-specific aminolysis reaction (Ulbrich et al, 1996). HPMA-
Gly-Gly-ONp was dissolved in double distilled water (2 mg ml–1)
and the solution of cathepsin B (2 mg ml–1) in 0.05 M phosphate
buffer, pH 7.2, was added at 4˚C with stirring. The reaction
mixture was stirred in the dark at pH 7.2 for 30 min. Then the pH
was carefully raised during 4 h by adding saturated sodium tetrab-
orate buffer up to pH 8.5 (to prevent enzyme denaturation). The
mixture was stirred for another 4 h and the reaction was termi-
nated by adding 1-amino-2-propanol (1/2 the equivalent related to
the original ONp content). The final yellow solution was acidified
by adding diluted HCl solution to pH 7.2. The conjugation reac-
tion was followed by UV spectrophotometry to detect the release
of ONp with time from the HPMA copolymer precursor (bound
ONp λ max = 270 nm; free ONp λ max = 400 nm). To remove free
polymer, free enzyme and other low molecular weight
compounds, the conjugate was purified at first by centriprep-50
(cut-off 50 KDa) or dialysis membrane Spectra/POR CE
(Cellulose Ester) sterile DispoDialyzer (Pierce & Warriner) MW
cut-off 50 KDa. The crude reaction mixture and the HPMA
copolymer-cathepsin B preparations were subject to SDS PAGE
analysis to ensure purity and the yield of the reaction determined
by BCA protein assay.
Determination of cathepsin B activity 
The in vitro activity of free and conjugated cathepsin B was first
determined using the tripeptide substrate Bz-Phe-Val-Arg-NAp.
Enzyme was incubated with substrate at 37˚C in citrate phosphate
buffer (0.2 M, pH 5.5) containing EDTA (10 mM) and reduced
glutathione (50 mM). NAp release was followed spectrophotomet-
rically at 410 nm. Subsequently the ability of free and conjugated
enzyme to cleave the high molecular weight substrate PK1 was
assessed by HPLC analysis. PK1 was incubated with cathepsin B
at 37˚C in a final volume of 1 ml: 400 µ l of PK1 (1 mg ml–1) in
citrate buffer (pH 5.5, 0.2 M), 100 µ l EDTA solution in buffer (10
mM), 100 µ l reduced glutathione (GSH 50 mM) and 400 µ l
HPMA copolymer-cathepsin B or free cathepsin B in buffer (1 mg
ml–1). Samples (100 µ l) were taken at various times, immediately
frozen in liquid nitrogen and stored frozen in the dark until
processed by HPLC (Wedge, 1990; Seymour et al, 1994) using
daunomycin as internal standard (100 ng). 
Tumour models 
All animal experiments were carried out according to the 
United Kingdom Co-ordinating Committee on Cancer Research
(UKCCCR) guidelines for the welfare of animals in experimental
neoplasia (UKCCCR guidelines, 1998). 
Body distribution of free and conjugated 125I-labelled-
cathepsin B 
Cathepsin B and HPMA-copolymer-Gly-Gly-cathepsin B were
125I-radiolabelled with Na[125I] iodide using chloramine-T. The
labelling efficiency and purity (<1% free [125I]iodide) of the 125I-
labelled products was then estimated using paper electrophoresis
and the specific activity of each product was determined (µ Ci
mg–1). Male C57BL/6J mice were inoculated s.c. with 105 viable
B16F10 cells. The tumour was allowed to establish until the area
was approximately 50–70 mm2 as measured by the product of 2
orthogonal diameters (c. 12 days). Free or conjugated cathepsin B
(100 µ l; 5 × 105 CPM) was injected into the tail vein of C57BL/6J
mice (n = 3 per time point). The mice were then placed in meta-
bolic cages and killed at times up to 48 h. Blood samples were
taken and organs dissected, weighed and homogenised in PBS.
Triplicate samples (1 ml) were then assayed for radioactivity. The
results were expressed as % dose injected. The blood volume of
the mouse was calculated assuming 5.7 ml blood/100 g mouse
(Dreyer and Ray, 1910). 
Evaluation of total and free doxorubicin after
administration of PK1 and the PDEPT combination to
mice bearing s.c. B16F10 
Male C57BL/6J mice were inoculated s.c. with 105 viable B16F10
cells. Animals bearing palpable B16F10 were injected i.v. with
PK1 (10 mg kg–1 dox-equiv.), or PK1 (10 mg kg–1 dox-equiv.)
followed after 5 h by free cathepsin B (3.63 mg kg–1) or HPMA
copolymer-Gly-Gly-cathepsin B (3.63 mg kg–1 weight equiv.
cathepsin B). They were killed at different time points up to 48 h
post-PK1 injection. The following tissue samples were dissected:
tumour, liver, kidneys, lung, heart, spleen, and urine and blood
samples were collected. Samples were weighed, homogenised in
PBS, mixed with 100 ng dnm. Total and free dox was analysed by
HPLC (Wedge, 1990; Seymour et al, 1994). 
Antitumour activity in B16F10 and COR-L23 models 
Mice (6–8 weeks) were inoculated s.c. with tumour cells (105
B16F10 cells into C57 mice or 106 COR-L23 cells into nu/nu mice).
When tumours became palpable (~25 mm2) treatment was initiated.
Groups (n = 5) were injected i.v. with PK1 (10 mg kg–1 dox-equiv.),
or PK1 (10 mg kg–1 dox-equiv.) followed after 5 h, by free cathepsin
B (3.63 mg kg–1) or HPMA copolymer-Gly-Gly-cathepsin B
(3.63 mg kg–1 weight equivalent of cathepsin B). Additional groups
were treated with saline, free dox (10 mg kg–1) or free cathepsin B
(3.63 mg kg–1). Animals were weighed and tumours measured daily.
Mice were killed when the tumour reached or surpassed the size of
289 mm2. The ratio (T/C) expressed as a percentage of the mean
survival time for a treated group of animals (T) compared with the
mean survival time of the control group (C) value was used to define
antitumour activity. Statistical significance was assessed using the
student’s t-test for small samples and P values < 0.05 were taken as
statistically significant.
RESULTS 
HPMA copolymer-Gly-Gly-cathepsin B conjugate were prepared
with a yield of 30–35% in respect of the bound protein. Whereas
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free cathepsin B has a band at 30 kDa on SDS PAGE the HPMA
copolymer-cathepsin B conjugates had a molecular weight in the
range 60–97 kDa. After purification no free enzyme was
detectable (results not shown). Against the Bz-Phe-Val-Arg-NAp
substrate, HPMA copolymer-cathepsin B retained 24.4% the
activity of free enzyme (Figure 3A) and with PK1 as substrate, the
cathepsin B conjugate retained 19.5% enzyme activity (Figure 3B).
The blood clearance of both the 125I-labelled enzyme and conju-
gate was biphasic. Clearance of 125I-labelled cathepsin B had a t1/2α
= 2.8 h and t1/2β = 8.9 h. The conjugate had a longer blood resi-
dence time (t1/2α = 3.2 h and t1/2β = 9.3 h). The conjugate blood
AUC was 1.3-fold greater than seen for free enzyme (Figure 4A)
and the tumour AUC was 3.6-fold greater (Figure 4B). 
After administration of PK1 to B16F10 melanoma-bearing mice
the levels of free dox detected in tumour were constant with time
at ~2500–5000 ng/tumour. When the HPMA copolymer-cathepsin
B conjugate was administered 5 h after PK1 there was a marked
increase in tumoural free dox levels (Figure 5). Over the 5–48 h
period this caused a 3.6-fold increase in the free dox AUC
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Figure 5 Levels of dox in B16F10 tumours after treatment with PK1 or the
PDEPT combination. The data shown represent free doxorubicin levels after
administration at time zero of PK1 (  ), PK1 followed by HPMA copolymer-
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compared to that seen after administration of PK1 alone (Figure 5).
Administration of free cathepsin B at the same protein dose (3.63
protein mg kg–1; ~5 times the enzyme activity) resulted in an
equivalent enhancement of dox liberation (results not shown).
Little free dox (< less than 10 ng) was detectable in the blood at
any time point (Figure 5) confirming that at 5 h after PK1 adminis-
tration, no PK1 was available in the circulation to act as a substrate
for the administered enzymes. Whereas, administration of HPMA
copolymer-cathepsin B led to increased levels of free dox in
tumour tissue there was no significant increase in dox levels in
normal tissues (Figure 6). 
A dox-equiv. dose of 10 mg kg–1 was chosen for all the treat-
ments used in preliminary experiments investigating the antitu-
mour activity of the PDEPT combination. Mice bearing s.c.
B16F10 showed increased survival when treated with free dox,
PK1 and the PDEPT combination (Table 1). Cathepsin B alone
was not active. During this study there were neither toxic deaths
nor animal weight loss (results not shown). A significant decrease
(compared with control mice group) was observed in tumour
growth rate in those animals treated with dox, PK1, and the
PDEPT combination (Figure 7). Nude mice bearing COR-L23
showed increased survival when treated with dox alone and the
PDEPT combination, although PK1 was not active in this model at
the dose used (Table 2). A significant decrease in the tumour
growth rate was observed after treatment of COR-L23 with either
dox or the PDEPT combination (Figure 8). 
DISCUSSION 
Although ADEPT and V/GDEPT have demonstrated improved
therapeutic activity in animal models and pilot human studies
(Bagshawe et al, 1995; Springer and Niculesco-Duvaz, 1996), a
number of inherent limitations have emerged. Antibody-enzyme
conjugates are often highly immunogenic (Sharma et al, 1992) and
individualised constructs are needed for tumours expressing
different antigens. The long plasma half-life of antibody-enzyme
leads to difficulties in optimisation of the dosing schedule for
subsequently administered prodrug. In some cases a second
clearing antibody has been required to prevent non-specific
prodrug activation in the circulation. V/GDEPT allows combina-
tion of oncogene targeting with chemotherapy, but it has inherent
problems associated with viral vectors, and the low and heteroge-
neous enzyme expression in vivo (Connors, 1995; McNeish et al,
1997). As the duration and reproducibility of enzyme expression is
difficult to evaluate on an individual patient basis, optimisation of
the schedule for prodrug administration again may be difficult.
PDEPT offers a number of advantages in comparison with
ADEPT and V/GDEPT HPMA copolymer-protein conjugates
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the PDEPT combination 
Table 1 Antitumour activity of PK1 and the PDEPT model administered i.v. to C57 mice bearing s.c. B16F10 murine
melanoma 
Treatment Dose (mg kg–1) Time to progression (Days ± SE) T/C (%) No. of toxic deaths 
Saline – 6.8 ± 0.5 100 0/5 
Doxorubicin 10 9.8 ± 0.9 144* 0/5 
Cathepsin B 3.63 8.4 ± 1.4 123NS 0/5 
PK1 + cathepsin B 10 9.2 ± 0.8 135* 0/5 
PK1 10 10.33 ± 0.3 152** 0/5 
PK1 + HPMA-cathepsin B 10 11.4 ± 1.2 168** 0/5 
Levels of significance * P ≤ 0.05, ** P ≤ 0.01, NS = no significant difference. 
Table 2 Antitumour activity of PK1 and the PDEPT model administered i.v. to nu/nu mice bearing s.c. COR-L23 non-
small cell lung carcinoma 
Treatment Dose (mg kg–1) Time to progression (Days ± SE) T/C (%) No. of toxic deaths 
Saline 19.6 ± 1.3 100 0/5 
Doxorubicin 10 25.4 ± 1.6 129* 0/5 
PK1 10 22.6 ± 1.4 115NS 0/5 
PK1 + HPMA-cathepsin B 10 24.8 ± 1.1 127* 0/5 
Levels of significance * P ≤ 0.03, NS = no significant difference. 
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(like PEGylated proteins) display little or no immunogenicity
(Flanagan et al, 1990). Additionally, the opportunity to administer
a polymeric prodrug first (clinical pharmacokinetics has
confirmed rapid plasma elimination whilst retaining the possibility
of tumour targeting) can circumvent the problems associated with
premature prodrug activation in the circulation. 
Using the model combination of PK1 and HPMA copolymer-
cathepsin B, this study has confirmed the feasibility of the 3 key
aspects of the PDEPT concept. (1) Synthesis of a polymer-enzyme
conjugate that retains activity against a polymeric prodrug, (2)
tumour targeting of both components by the EPR effect and (3)
spatial accessibility of polymer-enzyme to the polymeric prodrug
in the tumour interstitium. Synthesis of antibody-and polymer-
enzyme conjugates is often problematic. Conjugation typically has
low yield (10–15%) (Svensson et al, 1994; Melton et al, 1996) and
results in reduced enzyme activity. Ashihara et al (1978) showed
that the activity of PEG-L-asparaginase conjugates decreased
dramatically with increasing PEG molecular weight and in propor-
tion to the degree of PEG substitution. The semi-random aminol-
ysis method used to bind HPMA copolymer precursor to cathepsin
B resulted in conjugates with a high yield (30–35% protein conju-
gation) and also conjugates with retained enzyme activity in vitro
against both the low molecular weight and macromolecular
substrates (20–25%) (Figure 3). 
125I-Labelled cathepsin B had a longer half-life (t1/2α = 2.8 h)
anticipated from the values reported for other (mainly bacterial)
enzymes. This may be explained by the homology of the bovine
and the mouse cathepsin B. None the less, the 125I-labelled HPMA
copolymer-cathepsin B conjugate did show a longer blood circula-
tion (Figure 4A) consistent with the reduced cellular clearance
and/or increased resistance to proteolysis (Francis et al, 1992).
Increased circulation time led to improved conjugate tumour prob-
ably attributable to passive targeting by the EPR effect. 
Using the B16F10 model, Seymour et al (1994) showed that i.v.
administration of PK1 produced a total doxorubicin AUC that was
~17-fold higher than seen for free dox at equi-dose (5 mg kg–1). It
was also noted that dox liberation had a lag phase of 30–60 min
and thereafter the free doxorubicin levels plateaued. The same
basic pattern of PK1 doxorubicin release was observed here
(Figure 5). However, subsequent administration of HPMA
copolymer-cathepsin B (Figure 5) clearly led to a marked increase
in PK1 doxorubicin liberation. This observation confirms both
extracellular accessibility of the polymer enzyme to the polymer
prodrug and verifies retention of the conjugate enzyme activity in
vivo. Administration of free cathepsin B (the same protein dose
but ~5 times the enzyme activity) also led to intratumoural release
of doxorubicin from PK1 (Figure 5). The apparently greater
potency of the polymer-enzyme conjugate in this experiment was
simply consistent with the improved EPR-mediated targeting of
the conjugate compared with to free enzyme. 
It was considered important to ensure that the PDEPT combina-
tion would produce antitumour activity. Although the preliminary
studies reported here are limited – using a single treatment and the
same doxorubicin dose as used for the pharmacokinetic studies (10
mg kg) – they verify activity of the PDEPT combination in both
the B16F10 and COR-L23 tumour models. Previous studies using
the ADEPT system in a CC3 human choriocarcinoma xenograft
(Springer et al, 1991) clearly showed that antitumour activity
improved dramatically following optimisation of both schedule and
dose of the antibody-enzyme conjugate and the prodrug. Future
experiments with the HPMA copolymer-cathepsin B and PK1
model combination will optimise both HPMA copolymer-enzyme
and PK1 doses and also the length of the repeated cycle of admin-
istration. As we understand more of the clinical profile of PK1 in
the ongoing phase II studies it may be clinically interesting to
consider an activating enzymes as an adjunct to this therapy.
However, other PDEPT combinations involving non-mammalian
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L23 tumours. For both the key is saline (  ), dox (10 mg kg–1) (  ), PK1 
(10 mg kg–1 dox-equiv.) (  ) and PK1 (10 mg kg–1 dox-equiv.) + HPMA
copolymer-cathepsin B (3.63 mg kg–1 protein-equiv) (   ). Values represent
the median tumour size 
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enzymes are currently considered priority for development and
these include an HPMA copolymer-β -lactamase and a related
polymeric prodrug (Satchi et al, 1999). 
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